News Page

AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS)
Subscribe to the AIDSinfo At-a-Glance
e-newsletter to receive regular updates on the latest in HIV/AIDS treatment, prevention, and research.
  • NIH Grantees Overcome Hurdle to Kill HIV-Infected Cells Brought Out of Hiding
    "A major obstacle to curing people of HIV infection is the way the virus hides in a reservoir primarily of dormant immune cells called resting memory CD4+ T cells. One potential approach to curing HIV infection is to awaken these latent CD4+ T cells so they start making HIV proteins. This would alert the immune system that the cells are infected, and, in theory, generate an immune response that kills them. It has been unclear, however, whether typical immune mechanisms for killing virally infected cells would eliminate HIV-infected CD4+ T cells awakened from the HIV reservoir."
     
    To learn more about this study, view the NIAID news release
  • New CDC Fact Sheet and Slide Set on HIV Care Continuum Available
    The Centers for Disease Control and Prevention (CDC) recently published a new "Understanding the HIV Care Continuum" fact sheet and "HIV Care Continuum for the United States and Puerto Rico" slide set. The HIV care continuum is the series of steps from the time a person is diagnosed with HIV through the successful treatment of their infection with HIV medications. The fact sheet and slide set provide information and statistics on the continuum, including how CDC monitors the continuum.
  • Community Member Nominations Are Now Being Accepted for the Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents
    The HHS Panel on Antiretroviral Guidelines for Adults and Adolescents (or the Panel) is accepting nominations for new community members who represent the demographic diversity of the HIV epidemic in the United States. Selected candidates may assist the Panel in identifying and addressing aspects of HIV treatment that are unique to their constituencies.

    The candidate shall have knowledge and involvement in issues related to management of HIV-infected adults and adolescents, as evidenced by experience in HIV treatment education/advocacy or clinical/public policy initiatives related to HIV treatment. The successful candidates will serve a 4-year term beginning April 2015, with potential for reappointment for one additional term.  

    The Panel is a Working Group of the Office of AIDS Research Advisory Council of the National Institutes of Health. The Panel is composed of over 40 members who are clinicians, researchers, academicians, HHS representatives, and community representatives with expertise in HIV management in the United States. The Panel meets monthly via teleconferencing and annually in a face-to-face meeting to review and critically evaluate emerging scientific data relating to antiretroviral therapy and revise the Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. The latest guideline was published on November 13, 2014, and can be found at http://AIDSinfo.nih.gov

    Panel members are not financially compensated for their time commitment. 

    The nomination should include a resume and a letter of nomination or a letter of interest with specific reference as to how the nominee would contribute to the work of the Panel.  Self-nomination is welcome. Nominations and all supporting documents should be submitted electronically to Alice Pau, Pharm.D. (apau@niaid.nih.gov) by January 9, 2015.
     
  • Updated Fact Sheets Available From CDC
    The Centers for Disease Control and Prevention (CDC) recently updated the following four fact sheets:
     

    The fact sheets include information and statistics on diagnoses of HIV infection and AIDS in each population. Prevention challenges and information about CDC programs and campaigns are also included.

  • Scientific/Clinical Member Nominations Are Now Being Accepted for the Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents
    The HHS Panel on Antiretroviral Guidelines for Adults and Adolescents (or the Panel) is accepting nominations for new scientific/clinical members with expertise in HIV medicine.The Panel is seeking candidates with expertise in HIV clinical research and clinical care.

    Panel members critically evaluate new information and prepare guidelines revisions. The candidates should be recognized experts in their areas of interest. The successful candidates will serve a 4-year term beginning April 2015, with potential for reappointment for an additional term.

    The Panel is a Working Group of the Office of AIDS Research Advisory Council of the National Institutes of Health. The Panel is composed of over 40 members who are clinicians, researchers, academicians, HHS representatives, and community representatives with expertise in HIV management in the United States. The Panel meets monthly via teleconferencing and annually in a face-to-face meeting to review and critically evaluate emerging scientific data relating to antiretroviral therapy and revise the Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. The latest guideline was published on November 13, 2014, and can be found at http://AIDSinfo.nih.gov

    Panel members are not financially compensated for their time commitment.

    The nomination should include a curriculum vitae and a letter of nomination or a letter of interest with specific reference as to how the nominee would contribute to the work of the Panel. Self-nomination is welcome. Nominations and all supporting documents should be submitted electronically to Alice Pau, Pharm.D. (apau@niaid.nih.gov) by January 9, 2015.
     
  • FDA Approves Stribild Efficacy Supplement
    "On December 17, [2014], the Indications and Usage section of the STRIBILD (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir 300mg) label was updated to include patients who are virologically-suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure in order to replace their current regimen. Patients should have no known substitutions associated with resistance to the individual components of STRIBILD."
     
    More information is available: